H.C. Wainwright

Canoo Analyst Remains Bullish While Investors Punish The Stock On Disappointing Outlook
Rain Oncology's Phase 3 Data Casts Doubt On Other Trials: Analyst Reevaluate Their Views
Plug Power To Get A Big Boost From Inflation Reduction Act And $40B+ Microsoft Opportunity, Say Bullish Analysts
Rain Oncology's Phase 3 Data Casts Doubt On Other Trials: Analyst Reevaluate Their Views
Plug Power To Get A Big Boost From Inflation Reduction Act And $40B+ Microsoft Opportunity, Say Bullish Analysts
Why These Analysts Are Bullish On Plug Power Post-Earnings
Is Plug Power Justified In Sacrificing Near-Term Margin For Long-Term Outperformance?

H.C. Wainwright Recent News

Bullish Arbutus Biopharma Analyst Breaks Down Pipeline Opportunity
The expected start of combination clinical trials has H.C. Wainwright bullish on shares of Arbutus Biopharma Corp. (NASDAQ: ABUS). The Arbutus Analyst: Ed Arce raffirmed a Buy rating on shares of Arbutus Biopharma Corp. with a $10 price target. 
Why This ChemoCentryx Analyst Is Bullish
H.C. Wainwright analysts remain bullish on ChemoCentryx, Inc. (NASDAQ: CCXI) following an amended new drug application for avacopan. The ChemoCentryx Analyst: Edward White reaffirmed a  Buy rating on shares of ChemoCentryx, Inc. with a $28 price target. 
5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing
Biogen Inc.'s (NASDAQ: BIIB) Alzheimer's treatment Aduhelm was approved by the FDA Monday, sending the company's shares up over
Advertising, Acquisition And Potential Subscription Model Point To $6PT For Super League Gaming
On Thursday, esports company Super League Gaming Inc (NASDAQ: SLGG) received a bullish analyst initiation and comments on the company’s multiple avenues of growth.
3 Penny Stocks To Buy According To Top Stock Market Analysts
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Penny Stocks To Buy With Price Targets Up To 168% According To Analysts Maxim Group & H.C. Wainwright.
XpresSpa To Benefit From Improving Travel Trends, New Outlet Openings: Analyst
Shares of health and wellness services company XpresSpa Group Inc (NASDAQ: XSPA) were trading solidly higher Tuesday following a positive analyst move.&nbs
Breaking Down Novavax's Coronavirus Vaccine Data: 2 Analysts Takes
Novavax, Inc. (NASDAQ: NVAX) shares were roaring higher Friday after the company reported topline results from the late-stage trial of its coronavirus vaccine candidate in the U.K.
Why Plug Power's Lead In Fuel Cell, Hydrogen Space Could Create 'Outsized Winner'
Plug Power Inc (NASDAQ: PLUG) shares are primed for further gains, according to H.C. Wainwright, which issued a new Street-high price target for the fuel cell manufacturer.
Novavax Analysts Confident As Coronavirus Vaccine Candidate Heads To Phase 3 Study
Novavax, Inc.
Gilead Analysts Dissect Immunomedics Deal: 'Pricier But Bold Move Into Oncology'
Gilead Sciences, Inc. (NASDAQ: GILD) announced over the weekend a deal to buy Immunomedics, Inc.
Inovio Analyst Says Thermo Fisher Deal 'One Solid Step' Toward COVID-19 Vaccine Commercialization
Inovio Pharmaceuticals Inc (NASDAQ: INO), which has had a legal tussle with its South Korean CDMO, announced Tuesday an agreement with Thermo Fishe
After Mixed Q2 Report, Novavax Analyst Details Possible Coronavirus Vaccine Catalysts
Novavax, Inc. (NASDAQ: NVAX) released better-than-expected bottom-line results for the second quarter Monday, although revenue trailed estimates.
Applied DNA Analyst Says Coronavirus Testing, Vaccine Work Could Drive Major Upside
Shares of Applied DNA Sciences Inc (NASDAQ: APDN), which is in the race to develop a vaccine for the novel coronavirus, offer an attractiv
Novavax Analyst Says COVID-19 Vaccine Could Net $400M In Yearly Sales
Novavax, Inc. (NASDAQ: NVAX) shares are on a dream run this year amid catalysts including its COVID-19 vaccine program.
Inovio Analyst Downgrades COVID-19 Vaccine Developer, Says Risk Higher After Rally
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares have rallied strongly in late June, moving from $14.27 on June 19 to $31.25 on July 25, translating to a stellar gain of about 110%.
Sorrento Rallies On EUA Filing For Rapid COVID-19 Antibody Test Kit
Sorrento Therapeutics Inc (NASDAQ: SRNE) shares were headed higher Thursday following an announcement concerning its antibody test kit for SARS-CoV-2, the virus that causes COVID-19.
Inovio Analysts Bullish On Prospects For Coronavirus Vaccine, Biotech's Pipeline
A day after short seller Citron Research slammed Inovio Pharmaceuticals Inc (NASDAQ: INO), sell-side analysts lined up behind the
Sorrento Therapeutics Analyst Says Coronavirus Antibody Cocktail One Of Few Non-Vaccine Options
Sorrento Therapeutics Inc (NASDAQ: SRNE) shares spiked 158% Friday after the company disclosed that it has identified an antibody that demonstrate
5 ASCO Abstracts Moving Biopharma Stocks
The American Society of Clinical Oncology annual conference brings together oncology professionals, patient advocates, industry representatives, and major media outlets from across the globe. This year's meeting is is scheduled for May 29-31 and is organized as a virtual event due to the lockdowns and stay-at-home restrictions necessitated by the COVID-19 pandemic.
Inovio Analysts Tackle Coronavirus Vaccine Timeline, Funding, Pipeline After Q1 Report
Despite Inovio Pharmaceuticals Inc's (NASDAQ: INO) first-quarter miss Monday, the sell-side remains largely upbeat on company, which is developing a coronavirus
Novavax Analysts Say CEPI Funding 'Speaks Volumes' About Coronavirus Vaccine Development
Novavax, Inc. (NASDAQ: NVAX) announced Monday after the close an award of an incremental $384 million in funding by the Coalition for Epidemic Preparedness Innovations alongside forecast-beating first-quarter results.
Bidding War Sends Tetraphase Shares Soaring
Shares of nano-cap Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH), which have never really recovered from a steep sell-off triggered by an adverse clinical readout in late 2015, are surging Thursday after a second bidder emerged.
Inovio Analysts Project About 24% Upside Potential Amid Optimism On Coronavirus DNA Vaccine
Coronavirus vaccine play Inovio Pharmaceuticals Inc (NASDAQ: INO) announced the completion of enrollment in the Phase 1 trial of its COVID-19 DNA vaccine INO-4800 and